Phase II Evaluation of Pemetrexed in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian or Primary Peritoneal Carcinoma: A Study of the Gynecologic Oncology Group
Open accessThe DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Abstract
Purpose: To estimate the antitumor activity of pemetrexed in patients with persistent or recurrent platinum-resistant epithelial ovarian or primary peritoneal cancer and to determine the nature and degree of toxicities. Patients and Methods: A phase II trial was conducted by the Gynecologic Oncology Group. Patients must have had cancer that had progressed on platinum-based primary chemotherapy or recurred within 6 months. Pemetrexed at a dose of 900 mg/m 2 was to be administered as an intravenous infusion over 10 minutes every 21 days. Dose delay and adjustment was permitted for toxicity. Treatment was continued until disease progression or unacceptable adverse effects. Results: From July 6, 2004, to August 23, 2006, 51 patients were entered. A total of 259 cycles (median, four; range one to 19 cycles) of pemetrexed were administered, with 40% of patients receiving six or more cycles. Overall, the treatment was well tolerated. More serious toxicities (grade 3 and 4) included neutropenia in 42%, leukopenia in 25%, anemia in 15%, and constitutional in 15% of patients. No treatment-related deaths were reported. One patient (2%) had a complete and nine patients (19%) had partial responses, with a median duration response of 8.4 months. Seventeen patients (35%) had stable disease for a median of 4.1 months. Eighteen patients (38%) had increasing disease. Three patients (6%) were not assessable. Median progression-free survival was 2.9 months, and overall survival was 11.4 months. Conclusion: Pemetrexed has sufficient activity in the treatment of recurrent platinum-resistant ovarian cancer at the dose and schedule tested to warrant further investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vogelzang, N. J., Rusthoven, J. J., Symanowski, J., Denham, C., Kaukel, E., Ruffie, P., Gatzemeier, U., Boyer, M., Emri, S., Manegold, C., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.136 · Cited by 3,060 · cited 2×
“Pemetrexed administered as a single agent once every 21 days at 500 to 600 mg/m(2) has demonstrated activity in multiple tumor types, including mesothelioma, NSCLC, and colorectal, pancreas, bladder, head and neck, and cervical cancer.(16-20) Preliminary data from a trial in South Africa indicated a 21% response rate…”
BackgroundHanna, N., Shepherd, F. A., Fossella, F. V., Pereira, J. R., De Marinis, F., von Pawel, J., Gatzemeier, U., Tsao, T. C. Y., Pless, M., Muller, T., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.163 · Cited by 2,426 · cited 3×
“Pemetrexed administered as a single agent once every 21 days at 500 to 600 mg/m(2) has demonstrated activity in multiple tumor types, including mesothelioma, NSCLC, and colorectal, pancreas, bladder, head and neck, and cervical cancer.(16-20) Preliminary data from a trial in South Africa indicated a 21% response rate…”
BackgroundGordon, A. N., Fleagle, J. T., Guthrie, D., Parkin, D. E., Gore, M. E., & Lacave, A. J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.14.3312 · Cited by 1,211 · cited 1×
“4%; liposomal doxorubicin, 12%; and gemcitabine, 13% to 14%.(38-40) Pemetrexed has sufficient activity in the treatment of recurrent platinum-resistant ovarian cancer at the dose and schedule tested to warrant further investigation.”
BackgroundShih, C., Chen, V. J., Gossett, L. S., Gates, S. B., MacKellar, W. C., Habeck, L. L., Shackelford, K. A., Mendelsohn, L. G., Soose, D. J., Patel, V. F., et al. (1997) · PubMed · Cited by 601
Herbst, R. S., O'Neill, V. J., Fehrenbacher, L., Belani, C. P., Bonomi, P. D., Hart, L., Melnyk, O., Ramies, D., Lin, M., & Sandler, A. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.3026 · Cited by 396 · cited 1×
“In addition, pemetrexed seems to be synergistic with bevacizumab in some tumor cell lines and in vivo.(50-52) A phase I trial of pemetrexed, carboplatin, and bevacizumab for NSCLC showing its feasibility was also presented at the annual meeting of the American Society of Clinical Oncology.”
BackgroundRose, P. G., Blessing, J. A., Mayer, A. R., & Homesley, H. D. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.405 · Cited by 386 · cited 1×
“Responses were observed in 27% of patients treated with oral etoposide, 22% of patients treated with docetaxel, and 21% of those treated with weekly paclitaxel, whereas others showed limited or no activity (Table 4).(10,14,25) Pemetrexed (Alimta, LY231514) is an antifolate antineoplastic agent that exerts its action b…”
BackgroundSelf-citationLund, B., Hansen, O. P., Theilade, K., Hansen, M., & Neijt, J. P. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.20.1530 · Cited by 333
Bookman, M. A., Malmström, H., Bolis, G., Gordon, A., Lissoni, A., Krebs, J. B., & Fields, S. Z. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.10.3345 · Cited by 321 · cited 1×
“An active agent or agents so identified would be appropriate for evaluation in frontline trials, as was done in GOG 182.(24) The results of several of these prior GOG trials have been published.”
BackgroundPhase II Study of Pemetrexed Plus Carboplatin in Malignant Pleural Mesothelioma
Ceresoli, G. L., Zucali, P. A., Favaretto, A. G., Grossi, F., Bidoli, P., Del Conte, G., Ceribelli, A., Bearz, A., Morenghi, E., Cavina, R., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.3190 · Cited by 296 · cited 1×
“Trials in other tumor sites show that pemetrexed can be combined with both cisplatin and carboplatin.(41-48) A single-institution phase II trial of pemetrexed and carboplatin in platinum-sensitive recurrent ovarian cancer reported an overall response rate of 61%: one complete response (2%), 24 partial responses (59%),…”
BackgroundHomocysteine and methylmalonic acid: Markers to predict and avoid toxicity from pemetrexed therapy
Niyikiza, C., Baker, S. D., Seitz, D. E., Walling, J. M., Nelson, K., Rusthoven, J. J., Stabler, S. P., Paoletti, P., Calvert, A. H., & Allen, R. H. (2002) · PubMed · doi:10.25405/ncl.34649535 · Cited by 268
Cited by
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Marth, C., Landoni, F., Mahner, S., McCormack, M., Gonzalez-Martin, A., & Colombo, N. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx220 · Cited by 1,073
Cancer of the ovary, fallopian tube, and peritoneum: 2021 update
Berek, J. S., Renz, M., Kehoe, S., Kumar, L., & Friedlander, M. (2021) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.13878 · Cited by 514
Latest research and treatment of advanced-stage epithelial ovarian cancer
Coleman, R. L., Monk, B. J., Sood, A. K., & Herzog, T. J. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.5 · Cited by 489
Management strategies for recurrent platinum-resistant ovarian cancer
Naumann, R. W., & Coleman, R. L. (2011) · Drugs · doi:10.2165/11591720-000000000-00000 · Cited by 152
Szabova, L., Yin, C., Bupp, S., Guerin, T. M., Schlomer, J. J., Householder, D. B., Baran, M. L., Yi, M., Song, Y., Sun, W., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3834 · Cited by 122
“Platinum-resistant cancer recurs in approximately 25% of patients within 6 months (2), and the overall 5-year”
Integrated genomic analyses of ovarian carcinoma
The Cancer Genome Atlas Research Network (2011) · Nature · doi:10.1038/nature10166 · Cited by 129
Cancerous inhibitor of protein phosphatase 2A regulates cisplatin resistance in ovarian cancer
Li, W., Zhang, H., Yang, L., & Wang, Y. (2018) · Oncology Letters · doi:10.3892/ol.2018.9653 · Cited by 9
“The development of chemoresistance is a major challenge for patients with ovarian cancer (12).”
Dynamic visualization of multi-level molecular data: The Director package in R
Icay, K., Liu, C., & Hautaniemi, S. (2018) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2017.10.013 · Cited by 8
Metadata
- Authors
- Miller, D. S., Blessing, J. A., Krasner, C. N., Mannel, R. S., Hanjani, P., Pearl, M. L., Waggoner, S. E., & Boardman, C. H.
- Venue
- Journal of Clinical Oncology
- Published
- 2009-06-01
- Volume
- 27
- Issue
- 16
- Pages
- 2686-2691
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2036015352
- Cited by
- 186
- References
- 45
- FWCI
- 15.63
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.